Skip to main content
SpringerLink
Log in

Skin Reactions to Immune Checkpoint Inhibitors

  • Chapter
  • First Online:
Immunotherapy

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1342))

Abstract

Due to the novelty of immune checkpoint inhibitors, their cutaneous adverse events (AEs) have only been recently characterized. This, along with the substantial rate of cutaneous reactions, has left many clinicians without sufficient familiarity to diagnose and treat cutaneous AEs. Pruritus and rash are among the top five immune-related AEs reported in clinical trials for this class of therapy. Incidence varies between 35 and 60% for cutaneous AEs among the seven FDA-approved drugs used as monotherapy or combination therapy. Although only 2% are reported as grade 3 or 4 events with monotherapy, the incidence can be as high as 6–9% for combination therapy and the impact on quality of life can be significant for these patients. Of ipilimumab patients, 43.5% have a cutaneous AE, and, at our institution, 20% of them had a dose interruption as a result. This means potentially 9% of patients have dose interruption of ipilimumab because of their cutaneous AEs. In the following chapter, we review the categories of these drugs, common cutaneous effects, their grading, and management options.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric-Bernstam, F., & Hwu, P. (2020). Strategies for improving the management of immune-related adverse events. Journal for Immunotherapy of Cancer, 8(2), e001754.

    Article  Google Scholar 

  2. Villadolid, J., & Amin, A. (2015). Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Translational Lung Cancer Research, 4(5), 560–575.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. The New England Journal of Medicine, 381(16), 1535–1546.

    Article  CAS  Google Scholar 

  4. Long, G. V., Atkinson, V., Cebon, J. S., et al. (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): An open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202–1210.

    Article  CAS  Google Scholar 

  5. Sanlorenzo, M., Vujic, I., Daud, A., et al. (2015). Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatology, 151(11), 1206–1212.

    Article  Google Scholar 

  6. Teulings, H. E., Limpens, J., Jansen, S. N., et al. (2015). Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. Journal of Clinical Oncology, 33(7), 773–781.

    Article  CAS  Google Scholar 

  7. Attia, P., Phan, G. Q., Maker, A. V., et al. (2005). Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology, 23(25), 6043–6053.

    Article  CAS  Google Scholar 

  8. Sundaresan, S., Nguyen, K. T., Nelson, K. C., Ivan, D., & Patel, A. B. (2017). Erythema multiforme major in a patient with metastatic melanoma treated with nivolumab. Dermatology Online Journal, 23(9).

    Google Scholar 

  9. Kubicki, S. L., Welborn, M. E., & Patel, A. B. (2018). Toxic epidermal necrolysis during co-therapy with ipilimumab and nivolumab. Journal of Immunotherapy and Precision Oncology, 1(2), 78–81.

    Article  Google Scholar 

  10. Hodi, F. S., O’Day, S. J., McDermott, D. F., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363, 711–23.5.

    Article  CAS  Google Scholar 

  11. Robert, C., Thomas, L., Bondarenko, I., et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine, 364, 2517–2526.

    Article  CAS  Google Scholar 

  12. Robert, C., Ribas, A., Wolchok, J. D., et al. (2014). Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial. Lancet, 384, 1109–17.7.

    Article  CAS  Google Scholar 

  13. Robert, C., Long, G. V., Brady, B., et al. (2015). Nivolumab in previously untreated melanoma without BRAF mutation. The New England Journal of Medicine, 372, 320–330.

    Article  CAS  Google Scholar 

  14. Weber, J. S., D’Angelo, S. P., Minor, D., et al. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate037): A randomised, controlled, open label, phase 3 trial. The Lancet Oncology, 16, 375–384.

    Article  CAS  Google Scholar 

  15. Rizvi, N. A., Mazières, J., Planchard, D., et al. (2015). Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial. The Lancet Oncology, 16, 257–265.

    Article  CAS  Google Scholar 

  16. Garon, E. B., Rizvi, N. A., Hui, R., et al. (2015). Pembrolizumab for the treatment of non-small-cell lung cancer. The New England Journal of Medicine, 372, 2018–2028.

    Article  Google Scholar 

  17. Di Giacomo, A. M., Biagioli, M., & Maio, M. (2010). The emerging toxicity profiles of anti-CTLA-4 anti-bodies across clinical indications. Seminars in Oncology, 37(5), 499–507.

    Article  Google Scholar 

  18. Fujii, T., Colen, R. R., Bilen, M. A., et al. (2018). Incidence of immune-related adverse events and its association with treatment outcomes: The MD Anderson Cancer Center experience. Investigational New Drugs, 36(4), 638–646.

    Article  CAS  Google Scholar 

  19. Horvat, T. Z., Adel, N. G., Dang TO, et al. (2015). Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. Journal of Clinical Oncology, 33(28), 3193–3198.

    Article  CAS  Google Scholar 

  20. Coleman, E., Ko, C., Dai, F., Tomayko, M. M., Kluger, H., & Leventhal, J. S. (2019). Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal of the American Academy of Dermatology, 80(4), 990–997.

    Article  CAS  Google Scholar 

  21. Karri, P. V., Tahseen, D., & Patel, A. B. (2020). Treatment of checkpoint inhibitor-induced vitiligo in a patient with metastatic renal cell cancer. Dermatitis. Published online December 1.

    Google Scholar 

  22. Daxini, A., Cronin, K., & Sreih, A. G. (2018). Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clinical Rheumatology, 37(9), 2579–2584.

    Article  Google Scholar 

  23. Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016). Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities. RMD Open, 2(2), e000321.

    Article  Google Scholar 

  24. Messer, A., Drozd, B., Glitza, I. C., Lu, H., & Patel, A. B. (2020). Dermatomyositis associated with nivolumab therapy for melanoma: A case report and review of the literature. Dermatology Online Journal, 26(8).

    Google Scholar 

  25. Lacouture, M. E., Wolchok, J. D., Yosipovitch, G., Kähler, K. C., Busam, K. J., & Hauschild, A. (2014). Ipilimumab in patients with cancer and the management of dermatologic adverse events. Journal of the American Academy of Dermatology, 71(1), 161–169.

    Article  CAS  Google Scholar 

  26. Nayar, N., Briscoe, K., & Fernandez, P. P. (2016). Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with nivolumab in a patient with ipilimumab refractory meta-static melanoma. Journal of Immunotherapy, 39(3), 149–152.

    Article  Google Scholar 

  27. Welborn, M., Kubicki, S. L., Garg, N., & Patel, A. B. (2020). Twelve cases of acneiform eruptions while on anti-CTLA4 therapy. Supportive Care in Cancer, 28(6), 2499–2502.

    Article  Google Scholar 

  28. Kubicki, S. L., Welborn, M. E., Garg, N., Aung, P. P., & Patel, A. B. (2018). Granulomatous dermatitis associated with ipilimumab therapy (Ipilimumab associated granulomatous dermatitis). Journal of Cutaneous Pathology, 45(8), 636–638.

    Article  Google Scholar 

  29. Welborn, M. E., Kubicki, S. L., & Patel, A. B. (2018). Pyoderma Gangrenosum following initiation of immune checkpoint inhibitor therapy. Journal of Immunotherapy and Precision Oncology, 1(2), 82–84.

    Article  Google Scholar 

  30. Minkis, K., et al. (2013). The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology, 69(3), e121–e128.

    Article  CAS  Google Scholar 

  31. Ohtsuka, M., Miura, T., Mori, T., Ishikawa, M., & Yamamoto, T. (2015). Occurrence of psoriasiform eruption during nivolumab therapy for primary oral mucosal melanoma. JAMA Dermatology, 151(7), 797–799.

    Article  Google Scholar 

  32. Totonchy, M. B., Ezaldein, H. H., Ko, C. J., & Choi, J. N. (2016). Inverse psoriasiform eruption during pembrolizumab therapy for metastatic melanoma. JAMA Dermatology, 152(5), 590–592.

    Article  Google Scholar 

  33. Schaberg, K. B., Novoa, R. A., Wakelee, H. A., Kim, J., Cheung, C., Srinivas, S., & Kwong, B. Y. (2016). Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. Journal of Cutaneous Pathology, 43(4), 339–346.

    Article  Google Scholar 

  34. Jour, G., Glitza, I. C., Ellis, R. M., et al. (2016). Autoimmune dermatologic toxicities from immune check point blockade with anti-PD-1 antibody therapy: A report on bullous skin eruptions. Journal of Cutaneous Pathology, 43(8), 688–696.

    Article  Google Scholar 

  35. Naidoo, J., Schindler, K., Querfeld, C., et al. (2016). Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunology Research, 4(5), 383–389.

    Article  CAS  Google Scholar 

  36. Freites-martinez, A., Kwong, B. Y., Rieger, K. E., Coit, D. G., Colevas, A. D., & Lacouture, M. E. (2017). Eruptive keratoacanthomas associated with pembrolizumab therapy. JAMA Dermatology, 153(7), 694–697.

    Article  Google Scholar 

  37. Johnson, D., Patel, A. B., Uemura, M. I., et al. (2019). IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunology Research, 7(6), 860–865.

    Article  CAS  Google Scholar 

  38. Sowerby, L., Dewan, A. K., Granter, S., Gandhi, L., & Leboeuf, N. R. (2017). Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatology, 153(6), 603–605.

    Article  Google Scholar 

  39. Lonowski, S., Sachsman, S., Patel, N., Truong, A., & Holland, V. (2020). Increasing evidence for omalizumab in the treatment of bullous pemphigoid. JAAD Case Reports, 6(3), 228–233.

    Article  Google Scholar 

  40. Kaye, A., Gordon, S. C., Deverapalli, S. C., Her, M. J., & Rosmarin, D. (2018). Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatology, 154(10), 1225–1226.

    Article  Google Scholar 

  41. Bezinelli, L. M., Eduardo, F. P., Migliorati, C. A., et al. (2019). A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: Brief communication. Journal of Immunotherapy, 42, 359–362.

    Article  CAS  Google Scholar 

  42. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. (2008). http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 26 July 2016.

  43. Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., et al. (2018). Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36(17), 1714–1768. https://doi.org/10.1200/JCO.2017.77.6385

    Article  CAS  PubMed  Google Scholar 

  44. Hua, C., Boussemart, L., Mateus, C., et al. (2016). Association of vitiligo with tumor response in patients with meta-static melanoma treated with pembrolizumab. JAMA Dermatology, 152(1), 45–51.

    Article  Google Scholar 

  45. Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016). Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes. Clinical Cancer Research, 22(4), 886–894.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Anisha B. Patel & Omar Pacha

Authors
  1. Anisha B. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omar Pacha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anisha B. Patel .

Editor information

Editors and Affiliations

  1. Professor, Dept. of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Aung Naing

  2. Assistant Professor, Service Chief of Adult Allergy & Immunology, Division of Immunology, Allergy & Retrovirology Baylor College of Medicine and Texas Children’ Hospital, Houston, TX, USA

    Joud Hajjar

Rights and permissions

Reprints and permissions

Copyright information

© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Patel, A.B., Pacha, O. (2021). Skin Reactions to Immune Checkpoint Inhibitors. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1342. Springer, Cham. https://doi.org/10.1007/978-3-030-79308-1_11

Download citation

Publish with us

Policies and ethics

Search

Navigation